Get the Stockscreener App
5.9977
0.13%
0.0077
Kamada Ltd stock is traded at $5.9977, with a volume of 41,141.
It is up +0.13% in the last 24 hours and up +15.34% over the past month.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
See More
Previous Close:
$5.99
Open:
$6.04
24h Volume:
41,141
Relative Volume:
1.18
Market Cap:
$345.53M
Revenue:
$142.52M
Net Income/Loss:
$8.28M
P/E Ratio:
74.97
EPS:
0.08
Net Cash Flow:
$-1.54M
1W Performance:
+9.05%
1M Performance:
+15.34%
6M Performance:
+4.31%
1Y Performance:
+28.71%
1-Day Range:
$5.98
$6.0544
1-Week Range:
$5.49
$6.06
52-Week Range:
$4.58
$6.5291
Kamada Ltd Stock (KMDA) Company Profile
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-18 | Initiated | Chardan Capital Markets | Buy |
Kamada Ltd Stock (KMDA) Latest News
Kamada to Present at Stifel Healthcare Conference - TipRanks
Kamada to Present at the Stifel 2024 Healthcare Conference - GlobeNewswire
Earnings growth outpaced the 24% return delivered to Kamada (TLV:KMDA) shareholders over the last year - Simply Wall St
Blood Plasma Market to Grow by USD 15.9 Billion (2024-2028) as Innovative Solutions Address Global Blood Shortage; Report Highlights AI's Impact on Market TrendsTechnavio - The Malaysian Reserve
Global Healthcare & Medical Tourism News - Medical Tourism Magazine
Global Plasma Protein Therapeutics Market to Touch ~USD 40 Billion Mark by 2030 | DelveInsight - GlobeNewswire
What Jean-Philippe Mateta did after Daichi Kamada scored in Aston Villa 1-2 Crystal Palace, it was telling - We Are Palace
Kamada strike secures Quarter-Final spot - Holmesdale Online
Aston Villa 1-2 Crystal Palace: Daichi Kamada fires Eagles into last eight of Carabao Cupbut visitors lose - Daily Mail
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET - The Manila Times
Alvotech to Report Financial Results for the First Nine - GlobeNewswire
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19-20, 2024 - The Manila Times
Alvotech Meeting Investors and Presenting at the Jefferies - GlobeNewswire
Kamada (NASDAQ:KMDA) Shares Cross Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Kamada Ltd. Announces 2024 Annual General Meeting - TipRanks
Alpha 1 Lung Disease Market Projected to Reach $19.93 Billion by 2031 with 19.33% CAGR - WhaTech
Kamada Ltd. (NASDAQ:KMDA) Short Interest Update - MarketBeat
Lower Respiratory Tract Therapeutics Global Market Advancements Highlighted by Size, Insights Forecast, Tre... - WhaTech
Alpha 1 Antitrypsin Deficiency Treatment Market Size Is Booming Worldwide with Share, Size, Top Key Players - La Funcion mx
Japan's Daichi Kamada Confident in Chances of a World Cup Spot if They Beat Australia in Qualifiers - News18
Daichi Kamada says Japan can close in on World Cup place against Australia - Business Recorder
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® - The Manila Times
Kamada (NASDAQ:KMDA) Stock Crosses Below 200 Day Moving AverageShould You Sell? - MarketBeat
Equus Total Return And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity - Via News Agency
Camtek Ltd. And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity - Via News Agency
EastGroup Properties And 4 Other Stocks Have High Sales Growth And An Above 3% Return on Equity - Via News Agency
What Oliver Glasner thinks of Daichi Kamada after slow start to life at Crystal Palace - We Are Palace
Plasma Therapy Market Advancements Highlighted by Size, Share Analysis And Forecast To 2033 - WhaTech
Lisandro Martinez is branded a 'coward' by former Premier League defender after escaping red card for 'unneces - Daily Mail
United States Genetic COPD Market Analysis By Size and Application - Third Eye News
Kamada Ltd expands plasma operations in Texas - Investing.com
Kamada Ltd expands plasma operations in Texas By Investing.com - Investing.com UK
Kamada Opens New Plasma Center in Houston - TipRanks
Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston - GlobeNewswire
Kamada expands plasma collection operations in Texas - TipRanks
Kamada expands plasma collection operations in Texas with new site in Houston - Seeking Alpha
SASTRA signs MoU with Kaynes for semiconductor capacity building - Communications Today
Infra stock jumps 3% after receiving orders worth ₹ 1,003 Cr for multiple projects - Trade Brains
KEC International Boosts Market Presence with Rs 1,003 Crore New Contracts - PUNE.NEWS
India's KEC International rises on 10.03 bln rupee order wins - XM
KEC International shares surge 4% on new orders worth Rs 1,003 crore - Moneycontrol
KEC International has now won nearly 70% of the total orders it received in FY24 - CNBCTV18
Emphysema Treatment Market Innovations Investigated by Size, Share, Analysis, Trends 2024-2033 - WhaTech
'Give me my money', says Kedah winger Norde - New Straits Times
United States Alpha Antitrypsin Deficiency Treatment Market Analysis By Size and Application - Third Eye News
KDA FC Players Display ProfessionalismNafuzi - BERNAMA
Talking points from Crystal Palace’s 2-1 EFL Cup win at QPR – Nketiah opens account after Arsenal switch and Kamada yet to lay down midfield marker - South London News
Intravenous Immunoglobulin Global Market Size, Trends 2024-2033 - WhaTech
Kamada Ltd. (NASDAQ:KMDA) Shares Bought by Y.D. More Investments Ltd - MarketBeat
Kamada (NASDAQ:KMDA) Stock Price Passes Below 200-Day Moving Average of $5.50 - Defense World
Kamada (NASDAQ:KMDA) Shares Pass Below Two Hundred Day Moving Average of $5.50 - MarketBeat
Kamada Ltd Stock (KMDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):